ICL Haifa (F&C) Licenses Technology for Wastewater Treatment from MIGAL Galilee Research Institute

TEL AVIV, Israel, July 6, 2015 /PRNewswire/ --

ICL (NYSE and TASE: ICL), a global manufacturer of products that fulfill essential needs in the agriculture, processed food and engineered materials markets, today announced that its ICL Haifa subsidiary ("signed a license agreement with MIGAL Galilee Research Institute ("MIGAL") for the use of proprietary technology related to wastewater treatment.

Under the terms of the agreement ICL HAIFA will have the right to develop, manufacture and sell reagents developed by MIGAL to treat wastewater. The agreement between the parties follows the successful completion of a year-long pilot program conducted by MIGAL in conjunction with ICL's open innovation arm, ICL Innovation Ltd., to develop a method and unique component to help lower pollution levels of wastewater so that the water may be reused for irrigation. The technology will be deployed in agricultural products manufactured by ICL HAIFA for its existing and future customers.

MIGAL is an internationally recognized center for agro-innovation and metabolic engineering with expertise in plant-based platforms, wastewater treatment technologies, as well as clinical nutrition, precision agriculture, therapeutic molecules, chemical extractions, vaccine technologies and computational chemistry. MIGAL conducts interdisciplinary applied research that combines expertise in agro-technology, computer science and big data analysis, metabolic engineering, environmental and plant sciences, chemistry, biochemistry and microbiology.

ICL Innovation was established in 2014 to accelerate ICL's development of sustainable new products and processes, as well as to provide solutions for major global challenges, by benefiting from the full range of knowledge, creativity and initiative available throughout the world. By embracing the Open Innovation approach, ICL harnesses the power of collaboration with scientists/entrepreneurs worldwide to accelerate the company's growth. ICL's Open Innovation "Accelerator" augments the company's R&D organization which includes approximately 500 employees who work at IMI/TAMI Research Institute located in Haifa, Israel, and its other R&D facilities elsewhere in Israel as well as in in Germany, Holland and the US. To date, ICL Innovation has received over 500 submissions for collaboration from which it is currently working on 10 projects.